Current Appointments & Affiliations
Eleanor Easley Distinguished Professor in the School of Medicine
·
2023 - Present
Medicine, Medical Oncology,
Medicine
Professor of Medicine
·
2015 - Present
Medicine, Medical Oncology,
Medicine
Professor in Surgery
·
2015 - Present
Surgery,
Clinical Science Departments
Professor in Urology
·
2025 - Present
Urology,
Clinical Science Departments
Member of the Duke Cancer Institute
·
2003 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Price transparency & out-of-pocket payments for medications: Implications of associated delivery fees in the United States.
Journal Article Health Policy Open · June 2026 BACKGROUND: Price transparency has been cited as a tool to reduce out-of-pocket (OOP) payments to patients. These tools for prescription drugs often focus on the price to patients for the drug alone. However, costs associated with drug delivery (i.e. infus ... Full text Link to item CiteCytoplasmic versus nuclear localization of androgen receptor splice variant 7 as a predictor of benefit from androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer (PROPHECY trial).
Journal Article Prostate Cancer Prostatic Dis · April 2, 2026 BACKGROUND: Androgen receptor splice variant-7 (AR-V7), a constitutively active truncated protein, is linked to hormone therapy resistance. Nuclear AR-V7 in CTCs correlates with poor response and shorter progression-free survival (PFS) and overall survival ... Full text Link to item CiteReal-world analysis of androgen receptor inhibitors in US patients with nonmetastatic castration-resistant prostate cancer: DEAR-EXT study.
Journal Article Prostate Cancer Prostatic Dis · March 18, 2026 BACKGROUND: The real-world retrospective DEAR study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) demonstrated darolutamide was associated with lower risks of discontinuation and progression to metastatic castration-resistant ... Full text Link to item CiteRecent Grants
Lutetium Long-term Safety Follow-up study
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2023 - 2035A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MEVROMETOSTAT (PF-06821497) WITH ENZALUTAMIDE IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MEVPRO-3)
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2025 - 2030A Phase 2, Open-label Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants with PSMA PET-Positive Castration-Resistant Prostate Cancer
Clinical TrialPrincipal Investigator · Awarded by Convergent Therapeutics, Inc. · 2025 - 2030View All Grants
Education
Duke University ·
1992
M.D.